author-photo

Omar Serri

Université de Montréal

103

Papers

2919

Citations

Citation Trend

Filter By

Papers (77) Sort By

Journal Conference Others

Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study

2015 Pituitary
Show All
- Source
- Cite
- Save
Citations (51)
Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: A randomized, multicenter, open-label, phase I study

2014 The Journal of Clinical Pharmacology
Show All
- Source
- Cite
- Save
Citations (22)
Iatrogenic Cushing Syndrome in Patients Receiving Inhaled Budesonide and Itraconazole or Ritonavir: Two Cases and Literature Review

2013 Endocrine Practice
Show All
- Source
- Cite
- Save
Citations (32)
Failure of temozolomide and conventional doses of pegvisomant to attain biochemical control in a severe case of acromegaly

2012 Pituitary
Show All
- Source
- Cite
- Save
Citations (28)
Cancer detection in long-term follow-up of patients with acromegaly

2012
Show All
- Source
- Cite
- Save
Citations (0)
Cabergoline therapy for prolactinomas: is valvular heart disease a real safety concern?

2010 Expert Review of Cardiovascular Therapy
Show All
- Source
- Cite
- Save
Citations (12)
A Canadian multi-centre, open-label long-term study of Pegvisomant treatment in refractory acromegaly

2009 Clinical and Investigative Medicine
Show All
- Source
- Cite
- Save
Citations (6)
An unusual association of a sellar gangliocytoma with a prolactinoma

2008 Pituitary
Show All
- Source
- Cite
- Save
Citations (25)
Octreotide LAR for the treatment of acromegaly

2008 Expert Opinion on Drug Metabolism & Toxicology
- Sophie Vallette
- Omar Serri
Show All
- Source
- Cite
- Save
Citations (11)
Serum markers of cardiovascular risk in patients with acromegaly before and after six months of treatment with octreotide LAR

2008 Pituitary
Show All
- Source
- Cite
- Save
Citations (13)